Helius Therapeutics has today announced a supply agreement with the University of Auckland for a new Phase 2 trial into cannabis as a sleep aid for patients which chronic back pain.
New Zealand’s medical cannabis market grew a further 25% in 2025, according to the latest official figures, seeing the country cement its position as one of the lesser-discussed but most exciting markets on the planet.
The medical cannabis industries in Australia and New Zealand are continuing to evolve rapidly, with both markets showing signs of maturation, regulatory recalibration, and expanding export ambitions, according to new data.
With Europe on their radar, a delegation of New Zealand companies is preparing to attend Cannabis Europa later this month. Business of Cannabis caught up with them ahead of the event to explore how they plan to connect with European counterparts, and where they see the most promising opportunities on the horizon.
New Zealand’s largest producer of medicinal cannabis, Helius Therapeutics, has launched in the Australian market under the brand HTL.
Australia and New Zealand are undergoing contrasting reforms in their medical cannabis regulations.
This week (and perhaps the next several) is going to be overrun with political news from the US Presidential race – where the fate of democracy and decency is on the line.
It was two years ago that Canada entered the brave new world of legalization.
A pandemic, the death of a hero of justice and harrowing wildfires rightfully took attention away from cannabis last week. But that hasn’t stopped legalization and normalization efforts from moving forward on many, many fronts.
